Pharma Companies

Govt plans to bar cough syrups for kids under 2 amid safety concerns

Draft NFI 2026 bars use for children under two, discourages it below five, and mandates stricter testing of ingredients after contamination-linked deaths raised global alarm

IPM growth at 10.5% marks 5-qtr high on steady pricing, volume recovery

Indian pharma market's growth was led more by price increases that an uptick in consumption

Centre increases monitoring of weight-loss drugs, flags safety concerns

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

Sai Parenteral's to launch IPO on March 24; eyes ₹285 crore via fresh issue

Sai Parenteral's IPO comprises a fresh issue of ₹285 crore and an offer for sale (OFS) of 3.2 million equity shares

Dr Reddy's likely to launch generic semaglutide Obeda in India in March

Hyderabad-based Dr Reddy's has applied to trademark the Obeda brand and logo, a government filing showed

USFDA issues Form 483 with 4 observations for Piramal Pharma's T'gana plant

Piramal Pharma has said the US health regulator has issued Form 483 with four observations after inspecting its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) conducted an inspection of the company's Digwal (Telangana ) based plant from February 9, 2026, to February 13, 2026. At the conclusion of the inspection, the USFDA issued a Form-483, with four observations, Piramal Pharma said in a regulatory filing on Friday. These observations are related to enhancement in procedures and not related to data integrity and indicated to be classified as a VAI (voluntary action indicated), it added. The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines, the drug maker stated. Piramal Pharma remains committed to maintaining the highest standards of compliance and will work closely with the agency to comprehensively address all the observations, it added. As per the USFDA, Form 48

Dr Lal back on the acquisition trail, tests South India for opportunities

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions

French drugmaker Servier bets big on India as key global export hub

French drugmaker to commit €15 million annually to SPC development and exports for cardiometabolic and venous diseases

US market remained a drag for Indian pharma in Q3 amid pricing pressure

The US market stayed a weak spot for Indian pharma companies in Q3FY26 amid sustained pricing pressure in generics, heightened competition and product-specific challenges

Piramal Pharma flags early recovery signs in CDMO demand as Q3 loss widens

The company attributed the weaker performance largely to continued inventory destocking in one of its large on-patent commercial products, affecting its CDMO business

Govt eases drug R&D norms, allows pharma firms to skip test licences

Pharma companies will no longer ne required to seek a test licence and may proceed with pharmaceutical development upon submitting an online intimation to CDSCO, except in certain cases, as part of broad simplication notified by the Union Health Ministry. Union Health Ministry has notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at simplifying regulatory processes, reducing approval timelines, and enabling faster conduct of clinical research and pharmaceutical development in the country. The amendment is line with the directions of Prime Minister Narendra Modi to reduce regulatory burden and promote Ease of Doing Business, the ministry sais Under the existing regulatory framework, pharmaceutical companies are required to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) for the manufacture of small quantities of drugs intended for examination, research, or analysis purposes. Through the notified amendments, thi

Biocon raises ₹4,150 crore via QIP issue on strong investor demand

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon

Budget 2026-27: Health sector seeks tax relief, rationalised rates

Ahead of Budget 2026-27, healthcare, medtech and pharma firms seek tax relief, higher R&D incentives and stronger support for preventive care and domestic manufacturing

Supriya Life Sciences bets on regulated markets with new facility

The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets

Akums President Finance Rajkumar Bafna resigns citing Delhi pollution

The drugmaker said Bafna will step down on December 31, 2025, after citing Delhi's pollution levels in his resignation letter

Laurus Labs zooms 73% in 2025, hits new high; what's driving pharma stock?

Laurus Labs management said the fundamentals of the company's business remain strong, with sustained growth momentum in the Contract Development and Manufacturing Organization and Generic business.

RPG Life Sciences eyes GLP-1 entry, US market via plant acquisitions

The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches

Biocon to integrate Biocon Biologics in $5.5-bn tranx, pivots away from IPO

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Biocon to make Biocon Biologics a wholly owned subsidiary in $5.5 bn deal

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Cipla launches India's first integrated lung diagnostics, wellness centre

The Delhi facility offers over 60 advanced tests and aims to close critical gaps in respiratory diagnosis and care